- Home
- ITOS vs IMMP Comparison
ITOS vs IMMP Comparison
Compare ITOS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- IMMP
- Stock Information
- Founded
- ITOS 2011
- IMMP 1987
- Country
- ITOS United States
- IMMP Australia
- Employees
- ITOS N/A
- IMMP N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ITOS Health Care
- IMMP Health Care
- Exchange
- ITOS Nasdaq
- IMMP Nasdaq
- Market Cap
- ITOS 381.2M
- IMMP 221.2M
- IPO Year
- ITOS 2020
- IMMP N/A
- Fundamental
- Price
- ITOS $10.20
- IMMP $1.70
- Analyst Decision
- ITOS Hold
- IMMP Buy
- Analyst Count
- ITOS 6
- IMMP 1
- Target Price
- ITOS $10.60
- IMMP $7.00
- AVG Volume (30 Days)
- ITOS 836.6K
- IMMP 95.6K
- Earning Date
- ITOS 08-07-2025
- IMMP 02-27-2025
- Dividend Yield
- ITOS N/A
- IMMP N/A
- EPS Growth
- ITOS N/A
- IMMP N/A
- EPS
- ITOS N/A
- IMMP N/A
- Revenue
- ITOS $35,000,000.00
- IMMP $3,019,249.00
- Revenue This Year
- ITOS N/A
- IMMP $50.37
- Revenue Next Year
- ITOS N/A
- IMMP N/A
- P/E Ratio
- ITOS N/A
- IMMP N/A
- Revenue Growth
- ITOS 177.89
- IMMP 24.11
- 52 Week Low
- ITOS $4.80
- IMMP $1.32
- 52 Week High
- ITOS $18.13
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- ITOS 65.94
- IMMP 48.55
- Support Level
- ITOS $10.05
- IMMP $1.66
- Resistance Level
- ITOS $10.21
- IMMP $1.71
- Average True Range (ATR)
- ITOS 0.13
- IMMP 0.07
- MACD
- ITOS -0.07
- IMMP 0.01
- Stochastic Oscillator
- ITOS 96.67
- IMMP 82.61
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.